Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Other Non-Current Assets came in at $29.6 million in Q2 2026, down 4.85% on a YoY basis from $31.1 million in Q2 2025, and down 27.69% quarter-over-quarter from $40.9 million in Q1 2026.
Analysis
Roivant Sciences (ROIV) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported Other Non-Current Assets for 6 consecutive years, with $29.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets fell 4.85% year-over-year to $29.6 million; the trailing twelve-month figure through Jun 2026 stood at $29.6 million (down 4.85% YoY), and the FY2026 full-year result was $40.9 million, up 24.52% from the prior year.
- Other Non-Current Assets slipped to $29.6 million in Q2 2026 per ROIV's latest filing, from $40.9 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $320.2 million in Q3 2024 and bottomed at $11.9 million in Q3 2022.
- Historically, Other Non-Current Assets has averaged $57.3 million across 5 years, with a median of $34.2 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 543.1% in 2024, then sank 91.31% in 2025.
- Over 5 years, Other Non-Current Assets stood at $46.2 million in 2022, then rose by 1.35% to $46.8 million in 2023, then slipped by 27.68% to $33.9 million in 2024, then grew by 2.02% to $34.6 million in 2025, then fell by 14.4% to $29.6 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $29.6 million, $40.9 million, and $34.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Insmed | 27.84 Bn | 26.68 Bn | 358.27 Mn | 104.44 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 29.59 Mn |
| Mar 31, 2026 | 40.92 Mn |
| Dec 31, 2025 | 34.56 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 31.09 Mn |
| Mar 31, 2025 | 32.86 Mn |
| Dec 31, 2024 | 33.88 Mn |
| Sep 30, 2024 | 320.24 Mn |
| Jun 30, 2024 | 32.81 Mn |
| Mar 31, 2024 | 156.27 Mn |
| Dec 31, 2023 | 46.85 Mn |
| Sep 30, 2023 | 49.80 Mn |
| Jun 30, 2023 | 46.31 Mn |
| Mar 31, 2023 | 49.48 Mn |
| Dec 31, 2022 | 46.22 Mn |
| Sep 30, 2022 | 11.87 Mn |
| Jun 30, 2022 | 14.25 Mn |
| Mar 31, 2022 | 25.82 Mn |
| Dec 31, 2021 | 20.88 Mn |
| Sep 30, 2021 | 21.34 Mn |